anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Asthma is a chronic lung disease, which is characterized by recurrent obstruction, a hypersensitivity and a chronic inflammation of the airway. It is known that LCPUVAs could reduce the production of inflammatory mediators. In addition, LCPUVAs can improve pulmonary function, with a concurrent reduction in bronchodilator use in patients with asthma. Subjects suffering from episodic asthma and house dust mite (HDM) allergy usually have a normal lung function testing at rest and show a decrease in lung function when they are exposed to HDM. Bronchial allergen provocation models are well established in asthma research and allow the evaluation of anti-allergic and anti-asthmatic agents in relatively small sample sizes. In a previous study the investigators could show, that LCPUVAs could reduce exhaled NO after repeated BAP with HDM.

In this study the investigators will investigate the protective effect of LCPUVAs in a repeated BAP model. Clinical symptoms (nasal and bronchial), exhaled NO, decrease in lung function the early asthmatic reaction (EAR), the late asthmatic reaction (LAR) and blood parameters (Triglyceride and Cholesterin and mircro RNAs) will be measured before and after LCPUVA supplementation.
BACKGROUND: Sepsis remains a major cause of mortality in intensive care units (ICUs). Prompt diagnosis and effective management are imperative for better outcomes. In this systematic review and meta-analysis, we explore the potential of circulating cell-free DNA (cfDNA), as a promising tool for early sepsis detection and prognosis assessment, aiming to address limitations associated with traditional diagnostic methods.
METHODS: Following PRISMA guidelines, we collected relevant literature from thirteen databases. Studies were included if they analyzed quantitative diagnostic or prognostic cfDNA levels in humans in case of sepsis. We collected data on basic study characteristics, baseline patient demographics (e.g. age and sex), and cfDNA levels across different stages of sepsis. Pooled SMD with 95%-CI was calculated, and Comprehensive Meta-Analysis (CMA) software facilitated meta-analysis. Receiver operating characteristic (ROC) curves were generated to assess cfDNA's combined sensitivity and specificity in diagnostics and prognostics.
RESULTS: We included a final of 44 studies, of which, only 32 with 2950 participants were included in the meta-analysis. cfDNA levels were higher in septic patients compared to healthy controls (SMD = 3.303; 95%-CI [2.461-4.145], p<0.01). Furthermore, cfDNA levels were higher in non-survivors than survivors (SMD = 1.554; 95%-CI [0.905-2.202], p<0.01). Prognostic studies demonstrated a pooled sensitivity and specificity of 0.78, while diagnostic studies showed a sensitivity of 0.81 and a specificity of 0.87.
CONCLUSION: These findings show that cfDNA levels are significantly higher in sepsis patients compared to control groups and non-survivors in comparison to survivors among both adult and pediatric populations.
The present invention relates to a special preparation form using pennogenin composite as an active constituent. Said pennogenin composite solid molecule dispersing preparation is formed by the mass percent of 0.5 to 40% pennogenin composite and 60 to 99.5% cyclodextrin. Composites with molecular weight over 1000 are generally supposed to be hard buried by cyclodextrin due to their big molecular space volume. The present invention is characterized in burying the pennogenin composite in cyclodextrin in a dispersing state in single molecule with the dispersing degree over ten times smaller than that of nanometer grains, which is quickly disintegrated and dispersed and absorbed by human body after entering into gastrointestinal tract, which as a result, improves the biological utility ratio by over two times. And the invention is also characterized in overcoming the shortcoming of PEG solid dispersant easily aging which results in slow dissolving-out speed. The present preparation is mainly used to cure gynecological blood diseases including hemostasis, hematopoiesis and gynecological inflammation.
The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
The invention pertains to murine TLR9 and related TLR9s which include murine - specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically  functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonis ts of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression o r function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules whic h include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibito rs and agonists and antagonists of signaling mediated by TLR7 and TLR8.
The present invention relates to the fields of medicine and cancer therapy. The present invention more particularly relates to novel compounds which are generally useful as medicaments. In particular, the present invention relates to the use of these novel compounds to increase the presentation of Precursor Translation Product (PTP) derived antigens by cancer cells in a subject, typically to generate and present and to induce or stimulate an immune response in the subject. The present disclosure also relates to the use of such compounds, in particular for the preparation of a pharmaceutical composition and/or for allowing or improving the efficiency of cancer treatment in a subject in need thereof. Also disclosed are methods of preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. In addition, the invention provides kits suitable for use in preparing the compositions of the invention and/or performing the methods described herein.
Disclosed are exercise and muscle enhancing formulations of creatine with an insulin modulating agent such as arginine. Also included are precursers, biological equivalents, or intermediate products of arginine such as L-citrulline, L-ornithine, L-glutamine, or L-lysine, their salts, esters, peptides, dipeptides or complexes with other chemicals combined with creatine. The creatine and insulin modulating substance such as L-arginine are preferably in sustained-release form so as to modulate and facilitate the absorption and transport of the creatine to muscle via increased vasodilation. The sustained-release combination of creatine monohydrate and L-arginine free base prolong the time period for muscle perfusion and enhance the supply of creatine to the muscles especially during extended athletic activity or body building. The arginine or giological equivalent, due to its endogenous anti-oxidant capacity via nitric oxide also serves to preserve creatine kinase which is oxidized by free radicals. Creatine kinase is responsible for converting creatine to phosphocreatine which is stored and recycled in muscles.
Bleeding events are feared complications in patients with advanced liver diseases and are associated with morbidity and mortality. In this context, gastrointestinal bleeding, particularly upper gastrointestinal bleeding, has a special clinical importance. In addition to endoscopic measures for hemostasis, reducing portal pressure in particular is a key component of treatment. Although the standard coagulation parameters are often altered in patients with liver diseases, optimizing coagulation plays a secondary role. Typically, a bundle of measures are employed in patients with portal hypertensive bleeding, which nowadays in most cases can halt the bleeding and stabilize the situation. The measures include endoscopy, antibiotic treatment, vasopressor treatment and, if necessary, shunt placement (transjugular intrahepatic portosystemic shunt).
A central venous access (uncuffed nontunneled catheter, preferentially in the right jugular vein or femoral vein), a biocompatible membrane and bicarbonate dialysate will be used. The investigators will plan at least 3 sessions of 4 to 6 hours each per week with blood flow \> 200ml/min, dialysate flow\>500ml/min, high sodium concentration (\>145 mmol/L) and low temperature (35°C) in the dialysate. the investigators will recommend urea reduction ratio \> 65% for each session.
PURPOSE:To prepare the titled external agent free from organic solvent, and having high stability and absorbability, by compounding indomethacin, crotamiton, a specific nonionic surface active agent, a specific water-soluble polymer compound and purified water at specific ratios. CONSTITUTION:0.3-1.5pts.wt. of indomethacin (an anti-inflammatory and analgesic agent) is dissolved in a mixture of 1.0-10.0pts.wt. of crotamiton and 2- 15pts.wt. of a nonionic surface active agent (preferably a polyethylene-based agent) having an HLB of >=6, under heating. The solution is added to an aqueous gel obtained by dissolving 0.3-15pts.wt. of a water-soluble polymer exhibiting a viscosity of >=3.000cps at a concentration of <=10wt% (preferably carboxyvinyl polymer, etc.) in 59,5-96.4pts.wt. of purified water. The mixture is stirred to obtain the objective indomethacin-containing cream for external application, free from the smell of organic solvent nor stimulation to the skin and having excellent stability and absorbability.
This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
PURPOSE:To obtain the objective A1-RC1510 substance useful as an antitumor antibiotic substance for medicine, by culturing a microbial strain belonging to Actinomadura genus and capable of producing the novel antibiotic substance A1-RC1510. CONSTITUTION:A microbial strain belonging to Actinomadura genus and capable of producing A1-RC1510 substance such as A1-RC1510 strain is cultured in a medium containing carbon sources, nitrogen sources, inorganic salts, etc., under aerobic condition by submerged process. The objective novel antibiotic substance A1-RC1510 can be extracted from the cultured product with an organic solvent immiscible with water, e.g. ethyl acetate. The extract is purified e.g. by chromatography to obtain high-purity A1-RC1510 substance having the following properties. Molecular weight, 995 by FD-MS; melting point, 136-138 deg.C; soluble in methanol and ethanol; neutral pale yellow powder.
The invention provides a JMJD8 gene and an expression product for inhibiting growth of hepatoma cells. Specifically, the invention provides JmjC domain protein 8 (JMJD8) of prokaryotic expression. It proves that the protein is used to treat liver cancer through a cell growth experiment. According to the invention, JMJD8 over-expressed SMMC-7721 cells are obtained by a lentivirus-mediated system. It proves that the gene can be used for gene treatment of liver cancer through the growth experiment. In addition, a cell apoptosis experiment proves that the JMJD8 gene, the protein or its stimulant can be used for combined chemotherapy of liver cancer.
OBJECTIVE: There is an increased risk of skeletal muscle mass (SMM) loss among patients with stage 5 chronic kidney disease treated with maintenance hemodialysis (MHD). The reduced SMM considerably influences the development of protein-energy wasting (PEW). Patients who develop PEW have higher hospitalization and mortality rates than those without PEW. This study determined if key variables could predict SMM Index (SMM adjusted for height) in patients receiving MHD.
METHODS: We conducted a secondary analysis of cross-sectional data obtained from the Rutgers Nutrition and Kidney Database (n = 178). Data were used to calculate both SMM and SMM Index. Univariate and multiple linear regression models explored the relationship between SMM Index and the following variables: serum albumin, urea clearance normalized treatment ratio, normalized protein catabolic rate, serum creatinine, and urea reduction ratio (URR).
RESULTS: Most participants were Black/African American (82.9%), male (59.1%), and obese (39%), with a mean age of 55.9 ± 11.9 years. The median Subjective Global Assessment score was 5, indicating a lower risk of malnutrition. Participants had a mean SMM of 26.4 kg and a median SMM Index of 8.9 kg/m2. Univariate regression modeling found URR to be a significant predictor of SMM Index, with increases in the percentage of URR predicting lower SMM Index values. The adjusted regression modeling found similar results, with increases in URR percentage predicting declines in SMM Index.
CONCLUSION: This study found that URR was a predictor of SMM Index in patients receiving MHD. Further research is required to explore these relationships and provide clinicians with a more extensive array of tools to recognize early signs of SMM loss to prevent the progression of PEW.
Type 2 diabetes is a complex metabolic disorder that can cause serious damage to various organs. Impairment in cognitive functions is one of the common complications in patients with diabetes. Impairment in cognitive functions and significant dementia were found to be approximately 1.5 times more common in individuals with diabetes than individuals without diabetes. In particular, inadequate glycemic control, the frequency of hypoglycemia, vascular diseases, insulin resistance, inflammatory cytokines and oxidative stress stand out as possible causes. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family with growth factor properties. BDNF plays a critical role in cell differentiation, migration, and survivable synaptic plasticity of neurons. BDNF also has an important role in learning and memory processes through synapses in the hippocampus. BDNF levels have been shown to decrease in mild cognitive dysfunction or in late-onset Alzheimer's disease. In animal experiments, it has been observed that BDNF values increase with the use of metformin in Parkinson's disease. Similar results were obtained with vildagliptin, alogliptin, rosiglitazone, and exendin-4 in animal experiments.

The effects of drugs used in the treatment of diabetes on protecting or improving cognitive functions have been studied for a long time. Most of these studies are at the preclinical level. In previous studies with Glucagon-Like Peptide 1 (GLP-1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors, there are data that both glycemia and incretins improve cognitive functions with their effects on brain structure. Similar positive results are seen for thiazolidinediones. While hyperglycemia control leads to positive results in insulin and sulfonylurea group drugs, the frequency of hypoglycemia can have a negative effect. There is not enough data on SGLT2 inhibitors.

Studies with SGLT2 inhibitors have shown a decrease in HbA1c values, weight loss, and a decrease in both systolic and diastolic blood pressure. Encouraging results have been obtained with SGLT2 inhibitors in both cardiac and renal outcomes, with heart failure in the foreground. As a result of these data, they are recommended as drugs that should be used in the foreground following metformin, especially in diabetic patients with cardiac and renal diseases. Animal studies with empagliflozin and canagliflozin show that both agents reduce cognitive impairment.

Our aim is to examine the effect of SGLT2 inhibitor use on cognitive functions and BDNF, one of the neuroinflammatory markers.
Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
The present invention relates to a capecitabine immediate-release pellet and a preparation method thereof. The capecitabine immediate-release pellet includes the compositions of capecitabine, an excipient, a disintegrating agent and an adhesive. The particle size of the pellet is 0.1-10 mm. The extrusion granulator technology is used in the present invention to prepare the capecitabine immediate-release pellets and the pellets are directly filled into capsules, thus the production process is greatly simplified. The method is simple and reliable. The capecitabine immediate-release pellets prepared by the present invention are good in reproducibility and high in yield.
A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition containing both chlorine dioxide and chlorite ion, and a complex ion thereof. The chlorine dioxide level generally is in an effective range of ClO 2  concentration from about 10 ppm to a maximum of about 110 ppm. In a preferred embodiment, a physiological composition is provided in a thickened form to increase retention in the area being treated. The composition is preferably based on a standard saline solution converted to the oxychlorine composition just prior to use by sequential addition of aqueous concentrates of a chlorite salt, a hypochlorite salt combined with a physiological buffer-producing salt of a multibasic acid, and an acidifying agent, optionally including a thickening agent.
PURPOSE: A novel Leuconostoc mesenteroides isolated from Kimchi is provided to ensure bile acid resistance, acid resistance, and antifungal and antibacterial properties. CONSTITUTION: A Leuconostoc mesenteroides DSR Y9(KCCM 11142P) has antifungal and antibacterial functions. The strain is isolated from Kimchi. An antifungal or antibacterial composition contains the strain or a culture thereof. A food additive contains the strain or the culture. Foods contain the strain or the culture. The foods include Kimchi, fermented sausage, fermented picked foods, drink, baby foods, or daily products. The fermented foods are prepared using the strain or culture as a starter. A composition for feed contains the strain or culture.
Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
Bone releases calcium and phosphate in response to pro-inflammatory cytokine-mediated inflammation. The body develops impaired urinary excretion of phosphate with age and chronic inflammation given the reduction of the kidney protein Klotho, which is essential to phosphate excretion. Phosphate may also play a role in the development of the resistance of the parathyroid calcium-sensing receptor (CaSR) to circulating calcium thus contributing to calcium retention in the circulation. Phosphate can contribute to vascular smooth muscle dedifferentiation with manifestation of osteoblastogenesis and ultimately endovascular calcium phosphate precipitation. Thus phosphate, along with calcium, contributes to the calcification and inflammation of atherosclerotic plaques and the origin of these elements is likely the bone, which serves as storage for the majority of the body's supply of extracellular calcium and phosphate. Early cardiac evaluation of patients with chronic inflammation and attempts at up-regulating the parathyroid CaSR with calcimimetics or introducing earlier anti-resorptive treatment with bone active pharmacologic agents may serve to delay onset or reduce the quantity of atherosclerotic plaque calcification in these patients.
The acute pain crisis (APC) is the commonest complication of sickle cell disease (SCD). Severe episodes may require treatment in hospital with strong opioid analgesic drugs, combined with additional supportive care measures. Guidelines for APC management have been produced over the past two decades gathering evidence from published studies, expert opinion, and patient perspective. Unfortunately, reports from multiple sources indicate that guidelines are often not followed, and that acute care in emergency departments and on acute medical wards is suboptimal. It is important to understand what leads to this breakdown in health care, and to identify evidence-based interventions which could be implemented to improve care. This review focuses on recently published articles as well as information about on-going clinical trials. Aspects of care which could potentially make a difference to patient experience include availability and accessibility of individual care plans agreed between patient and treating specialist, innovative means of delivering initial opioids to reduce time to first analgesia, and availability of a specialist unit away from the ED, where expert care can be delivered in a more compassionate environment. The current evidence of improved outcomes and health economic advantage with these interventions is inadequate, and this is hampering their implementation into health care systems.